Clinical Studies
The efficacy of the NMDA receptor antagonist memantine in moderate to severe AD is demonstrated in placebo-controlled double-blind studies performed in accordance with international guidelines. In the three main domains - cognition, activities of daily living, clinical global impression - memantine therapy led to significant and clinically relevant improvements. Success compared to placebo was achieved even in the treatment of patients with severe AD after just 4 weeks' treatment.
Clinical studies with memantine show
- Benefit in cognitive and psychomotor functioning
- Benefit in activities of daily living
- Reduction of care dependence
- Excellent tolerability
